Key Takeaway: The article discusses the results of a phase 2/3 open-label pediatric substudy of Arimoclomol in infants diagnosed with Niemann-Pick disease type C. The findings suggest that Arimoclomol may provide therapeutic benefits for this rare condition. This study highlights the ongoing efforts to develop treatments for pediatric patients with challenging genetic disorders.
Price reaction · baseline $12.68 (2026-06-22T16:20:00.000Z) · hit during market hours · 1 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-0.2%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows promise in treating Niemann-Pick disease type C in infants.
The study results indicate potential benefits for pediatric patients.
Phase 2/3 substudy demonstrates a commitment to addressing rare diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy
Molecular Genetics and Metabolism Reports - 6/19/26
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is being studied for its potential to treat Niemann-Pick disease type C.
What were the results of the study?
The study indicated that Arimoclomol may provide therapeutic benefits for infants.
What type of study was conducted?
A phase 2/3 open-label pediatric substudy was conducted.
Who were the subjects of the study?
The study focused on infants diagnosed with Niemann-Pick disease type C.